{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:12:18Z","timestamp":1783098738638,"version":"3.54.6"},"reference-count":41,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    <jats:italic toggle=\"yes\">Legionella<\/jats:italic>\n                    pneumonia is a significant cause of community-acquired pneumonia that often requires timely and effective treatment. While fluoroquinolones and macrolides are the recommended first-line therapies, doxycycline offers an alternative with favorable pharmacokinetics, safety, and minimal drug-drug interactions.\n                    <jats:bold>Methods:<\/jats:bold>\n                    We describe three hospitalized patients with\n                    <jats:italic toggle=\"yes\">Legionella<\/jats:italic>\n                    pneumonia who received doxycycline monotherapy.Clinical outcomes, including symptom resolution and survival, were assessed at 60 days. A literature review was also performed for studies published between 1980 and 2025 that evaluated doxycycline for Legionella infection.\n                    <jats:bold>Results:<\/jats:bold>\n                    All three patients achieved clinical improvement with doxycycline monotherapy, with resolution of presenting symptoms and survival at 60 days post-hospitalization. The literature review identified limited clinical data on doxycycline for Legionella pneumonia. In vitro data suggested that doxycycline may have lower bactericidal activity than fluoroquinolones, although its pharmacological profile and tolerability support its consideration in select cases.\n                    <jats:bold>Conclusion<\/jats:bold>\n                    : Doxycycline monotherapy was associated with favorable outcomes in three cases of Legionella pneumonia. Although the evidence remains sparse, doxycycline may represent a viable alternative when first-line therapy is contraindicated. Further research is required to define its role in the treatment of\n                    <jats:italic toggle=\"yes\">Legionella<\/jats:italic>\n                    pneumonia.\n                  <\/jats:p>","DOI":"10.1177\/87551225251366324","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T07:31:16Z","timestamp":1756625476000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Doxycycline for\n                    <i>Legionella<\/i>\n                    Pneumonia: Expanding Treatment Horizons Through a Case Series and Narrative Review"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5402-0240","authenticated-orcid":false,"given":"M. Gabriela","family":"Cabanilla","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA"},{"name":"Department of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen C.","family":"Scheibner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge R.","family":"Mera","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"American Thoracic Society. Top Pneumonia Facts. American Thoracic Society; 2019. Accessed January 6 2025. https:\/\/www.thoracic.org\/patients\/patient-resources\/resources\/top-pneumonia-facts.pdf"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500245"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19031907"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371006"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60216-0"},{"key":"e_1_3_3_8_2","unstructured":"Legionella (Legionnaires\u2019 Disease Pontiac Fever). CDC. Reviewed March 25 2021. Accessed July 21 2025. https:\/\/www.cdc.gov\/legionella\/php\/surveillance\/index.html"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01565-7"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2016.00175"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198700341-00015"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/22.Supplement_B.155"},{"issue":"9","key":"e_1_3_3_13_2","first-page":"1014","article-title":"Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia","volume":"43","author":"Wiesner B","year":"1993","unstructured":"Wiesner B, Wilen-Rosenqvist G, Lehtonen L. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia. Arzneimittelforschung. 1993;43(9):1014-1017.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.4.499"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.3.266"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01073.x"},{"issue":"2","key":"e_1_3_3_17_2","first-page":"205","article-title":"Antibiotic courses for common infections: recommendations from the ACP","volume":"105","author":"Dakkak M","year":"2022","unstructured":"Dakkak M, Sabharwal M. Antibiotic courses for common infections: recommendations from the ACP. Am Fam Physician. 2022;105(2):205-206.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.5847\/wjem.j.1920-8642.2023.063"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.05.002"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03759.x"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-020-03870-3"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.12.013"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1272773"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01972-19"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.4.757"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198206000-00001"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/23.1.123"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/16.2.199"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198815060-00001"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.02.015"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.09.005"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02176-12"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2023.09.007"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1127"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4873"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit439"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183813"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1362938"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2016.11.011"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003304"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.10.009"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.10.014"}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225251366324","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225251366324","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225251366324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:33:29Z","timestamp":1777602809000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225251366324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/87551225251366324"],"URL":"https:\/\/doi.org\/10.1177\/87551225251366324","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]}}}